{"disease":{"id":"pancreatic-malignant-neoplasm-primary","name":"pancreatic malignant neoplasm primary"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04637256","title":"Evaluation of Outcomes from Treatment of Benign or Malignant Gastroesophageal Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Methodist Health System","has_results":false},{"nct_id":"NCT03788382","title":"Failure to Adjuvant Therapy After Pancreatic Resection for Pancreatic Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":317,"lead_sponsor_name":"Universita di Verona","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04673448","title":"Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT03878524","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}